miR-204-5p inhibits the occurrence and development of osteoarthritis by targeting Runx2

JIAQING CAO, XINYOU HAN, XIN QI, XIANGYUN JIN and XIAOLIN LI

Department of Orthopedic Surgery, The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China

Received September 26, 2017; Accepted July 23, 2018

DOI: 10.3892/ijmm.2018.3811

Abstract. One of the hallmarks of osteoarthritis (OA) development is endochondral ossification, in which Runt-related transcription factor-2 (Runx2) is aberrantly expressed. Runx2 was previously identified to be regulated by microRNA-204-5p (miR-204-5p). The aim of the present study was to investigate the potential function of miR-204-5p regulating Runx2 during the development of OA and the underlying molecular mechanism. The expression levels of miR-204-5p and Runx2 were determined in tissue specimens. Rat OA models were established by transecting the anterior and posterior cruciate ligaments and removing the meniscus. Rats were treated with miR-204-5p agomir and miR-204-5p negative control (NC). All in vitro experiments were performed using rat primary chondrocytes and the SW-1353 human bone chondrosarcoma cell line. It was identified that the expression of miR-204-5p was significantly decreased, whereas Runx2 was significantly increased, in human OA tissues compared with in non-OA tissues, and levels were inversely associated with each other in primary chondrocytes and chondrosarcoma cells. Overexpression of miR-204-5p decreased the proliferation of chondrocytes and SW-1353 cells. Using a luciferase reporter assay, Runx2 was identified to be a direct target of miR-204-5p in chondrocytes and overexpressed miR-204-5p altered the expression of collagens II, X and matrix metalloproteinase (MMP)-1 and MMP-13 in primary chondrocytes and SW-1353 cells. Histological analysis revealed that miR-204-5p treatment ameliorated the OA-like phenotype that is reflected by assessment of cartilage thickness and Mankin's score. Runx2 expression was gradually increased as the rats increased in age. At 10 weeks of miR-204-5p agomir treatment, altered expression levels of collagens II and X, cartilage oligomeric matrix protein fragment, aggrecan, MMP-1 and MMP-13 were observed in the treatment group compared with the NC group. In conclusion, the results of the present study indicated that miR-204-5p decreases chondrocyte proliferation and ameliorates the OA-like phenotype in rats with surgically induced OA by targeting Runx2.

Introduction

Chondrocytes, the cellular component of human articular cartilage, serve an important function in maintaining the matrix components under normal conditions (1). In healthy articular cartilage, chondrocytes resist proliferation and terminal differentiation. By contrast, chondrocytes in diseased cartilage progressively proliferate and develop hypertrophy (2). Differentiation of chondrocytes triggers a disturbed cartilage homeostasis favoring articular cartilage degradation and formation of osteophytes.

Gene expression during chondrocyte maturation is controlled by transcription factors. Runt-related transcription factor 2 (Runx2) is one of the central positive regulators within the transition phase from proliferating to hypertrophic chondrocytes (2). It is responsible for proliferation and differentiation of chondrocytes, and its loss contributes to chondroclast development by regulating the nuclear factor xB signaling pathways (3). Runx2/3 double-deficient mice lack hypertrophic chondrocytes in all parts of the skeleton (4). Runx2 is overexpressed in OA cartilages and implicated in DNA methylation (5,6), and enhancement of Runx2 stimulates hypertrophic chondrocyte differentiation (7).

MicroRNAs (miRNAs/miRs) are small non-coding RNAs that regulate gene expression by binding to 3'-untranslated regions (3'-UTRs) of specific mRNA of target genes (8). The function of miRNAs has been identified to be associated with a variety of inflammatory pathogenesis, including cartilage disease and chondrogenesis (9). It was demonstrated that miR-204-5p is sponged by the long non-coding RNA (IncRNA) taurine upregulated 1 to promote osteoblast differentiation by upregulating Runx2 (10). In osteogenesis of rat bone marrow mesenchymal stem cells, the IncRNA TCONS_00041960 was identified to interact with miR-204-5p to regulate Runx2 (11). In mesenchymal progenitor cells, chondrogenic and osteogenic cell lines, it has also been identified that miR-204 is able to bind to the 3'-UTR of the Runx2 gene and regulate its
expression (12,13). Another study identified that, among the genes involved in osteoblast and osteoclast activity, changes in miRNAs are involved in osteoblastogenesis, including miR-204-5p, but Runx2 was unchanged in patients with clinically and biochemically confirmed acromegaly (14). However, to the best of our knowledge, no previous study has investigated the potential function of miR-204-5p and its association with Runx2 in OA. Therefore, we hypothesized that there may be a regulation between miR-204-5p and Runx2 in OA development, and, if so, investigate how the axis of miR-204-5p/Runx2 may function. The aim of the present study was to investigate the effect of miR-204-5p in OA cells and rats with OA, as well as the underlying molecular mechanism.

**Materials and methods**

**Human tissue specimens and ethical statements.** Normal adult articular cartilage were obtained from patients with idiopathic osteonecrosis of femoral condyle (n=7; 3 males and 4 females; age range, 63-75 years) who did not receive radiographic or any intra-articular treatment. Cartilages of the femoral head and knee joint were obtained from patients with OA who underwent total knee arthroplasty (n=10; 4 males and 6 females; age range, 59-77 years). Since cartilage degradation and/or osteophyte formation are the characteristics of OA development, necrotic bone tissues were selected as negative control (NC), in which cartilage degradation or osteophyte formation cannot be observed. The samples were then stored at -80°C until analysis. All human studies were approved by the institutional ethics review board of The Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University (Shanghai, China). Written informed consent was obtained from each patient.

**Animal models.** All animal procedures were approved by the Animal Care and Use Committee of the Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University. In total, 45 12-week-old male Sprague-Dawley (SD) rats (weighing 200-300 g) (Shanghai Laboratory Animal Center, Shanghai, China) were housed in groups of two under a 12 h light/12 h dark cycle at room temperature with food and water ad libitum. All animals were randomly divided into three groups: OA miR-204-5p agomir treatment group (n=15), OA NC group (n=15) and sham surgery group (n=15). The rats in the miR-204-5p agomir treatment or NC group were subjected to one-time injection of miR-204-5p agomir (800 pmol) or NC (800 pmol) into the joint 6 h before surgery, and 5 weeks later the same volume of the compounds was injected again. Rats were sacrificed at 5, 10 and 15 weeks after surgery. The OA model was established by transecting the anterior and posterior cruciate ligaments and removing the meniscus as described previously (15). Sham surgery consisted of all aforementioned steps except for ligament transection.

**Isolation and culture of cells.** Primary chondrocytes were isolated from newborn SD rats as described previously (16). Briefly, following sacrifice of the rats, the articular cartilage of the knee joint was removed, and attached muscle, perichondrium and connective tissue were removed. The cartilages were shredded, washed in PBS and digested with trypsin for at 37°C. Subsequently, they were washed with PBS and digested with type II collagenase solution. Dissociated cells were passed through a 100-mesh nylon mesh sieve and centrifuged at 400 x g for 8 min at room temperature. The cells were resuspended in Dulbecco’s modified Eagle’s medium (DMEM)/Ham’s F12 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The isolated chondrocytes (1x10^6 cells/ml) in culture flasks were counted and cultured at 37°C. The medium was refreshed every 48 h.

The SW-1353 human bone chondrosarcoma cell line was obtained from the Institute of Biochemistry and Cell Biology (Shanghai, China). Cells were cultured in DMEM with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and incubated at 37°C for 24 h before transferring onto 96-well plates at 9x10^3 cells/well.

**Cell counting kit-8 (CCK-8) assay.** Cell viability was assessed using a CCK-8 assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) assay. Briefly, cells were seeded onto 96-well plates at a density of 7,000 cells/well and incubated at 37°C for 24 h. Following transfection, CCK-8 solution was added to each well prior to incubation for 1 h at 37°C in the dark. The optical density values were determined at dual wavelengths of 450 and 630 nm (reference wavelength) to ascertain cell viability using a microplate reader (Thermo Labsystems, Santa Rosa, CA, USA).

**Plasmid construction and transfection of miRNA.** Human chondrocytes and SW-1353 cells were transfected with the miR-204-5p mimic (uuccuaauucucauugcu; Ambion; Thermo Fisher Scientific, Inc.) or antisense inhibitor anti-miR-204 (aggcaaug gauagcaaaagg; Ambion; Thermo Fisher Scientific, Inc.) at a concentration of 50 nM using Lipofectamine® 2000 transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.). For the control, cells were transfected with Lipofectamine® RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.) with a scrambled control miRNA.

The reporter plasmid was constructed by inserting Runx2 mRNA 3’-UTRs downstream of the firefly luciferase gene in the pmirGLO vector (Promega Corporation, Madison, WI, USA). Cells were seeded onto plates, incubated at 37°C and were harvested when the cell monolayer reached 70% confluency. Recombinant plasmid (200 ng) and miR-204-5p mimic (200 ng) were co-transfected into the cells. Plasmid suspension and Lipofectamine 2000 reagent were incubated in FBS-free DMEM for 20 min and then added to 48-well plates. After 6 h of incubation, DMEM was added to the wells.

**Luciferase gene reporter assay.** Primary rat chondrocytes were harvested and subjected to luciferase activity assays as described previously (17). Briefly, after 48 h of incubation, growth medium was removed and cells were washed with PBS twice. Cells were broken down by adding 100 µl passive lysis buffer (Guanzhou RiboBio Co., Ltd., Guangzhou, China) to each well and placed on ice for 30 min. Cell lysates were transferred to 96-well microplates. Dual Luciferase assay kits (Promega Corporation) were used according to the manufacturer’s protocol and luciferase activity was determined using a microplate reader at 540 nm. An equal volume of Dual-Glo® Stop&Glo Reagent (Promega Corporation) was added to the wells, and Renilla luminescence was determined...
48 h after transfection using the dual-luciferase reporter assay system (Promega Corporation). Rat Runx2 3'-UTR (NM_001278483.1, positions 5,251-5,575) was cloned into the psiCHECK™-2 vector (Guangzhou RiboBio Co., Ltd.), and the primers used to construct the plasmid were: Forward, 5'-ccgCTCGAGtaacctgacctatcttcta-3' (capitals denote the XhoI site) and reverse, 5'-ataaaggCGGCGCCGcatagggga gaaatgc-3' (capitals denote the NotI site). The experiments were performed in triplicate.

Immunohistochemistry (IHC) and Safranin O/Fast Green staining. Tissue specimens were fixed in 10% formaldehyde at 4°C for 7 days, decalcified in 4.13% EDTA at 4°C for 14 days and then embedded in paraffin. Joints were sliced into 5 µm continuous sections and stained with Safranin O/Fast Green and antibody against Runx2 (cat. no. ab2398; 1:200; Abcam, Cambridge, UK). Histomorphometric analysis was performed with quantification of the Safranin O-positive cartilage area and its thickness, and Runx2-positive cells using Pro Plus software (version 6.0; Media Cybernetics, Inc., Rockville, MD, USA). OA scoring was analyzed using a modified Mankin’s Score system (18,19).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Cartilages of the femoral head and knee joint were obtained from patients with OA. Control articular cartilages were obtained from patients with idiopathic osteonecrosis of the femoral condyle. Cartilage from normal and OA donors were milled to a fine powder in liquid nitrogen. Total RNAs and miRNA were extracted from tissue samples obtained from patients and rats with OA and from cell cultures using TRIzol® (Thermo Fisher Scientific, Inc.). miRNA was purified using an miVana isolation kit (Ambion; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol. The purity of total RNAs and miRNA was determined using a NanoDrop instrument (Thermo Fisher Scientific, Inc.). For detecting the expression level of Runx2 mRNA, the cDNA was prepared from 2 µg total RNA using a cDNA synthesis kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Expression of mature miRNA was quantified using a TaqMan miRNA assay kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). Purified miRNA was reverse-transcribed using a TaqMan miRNA reverse transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). Expression of the mRNA level was quantified by adding 1 µg synthesized first-strand cDNA in a 20-µl reaction mixture using the PrimeScript RT reagent kit (Takara Biotechnology Co., Ltd., Dalian, China). qPCR was performed using a PCR instrument (7300 Step One Plus; Applied Biosystems; Thermo Fisher Scientific, Inc.). Thermocycling conditions were as follows: 40 cycles of 95°C for 5 sec and 60°C for 34 sec. As an internal control, U6 primers (forward, 5'-CTCGAGTCGACAGGACA-3' and reverse, 5'-AACGCTTCAAGATTTTGCGT-3') were used for RNA template normalization. The relative expression of each target gene was calculated using the 2^(-ΔΔCq) method (20). The stem-loop primer for human miR-204-5p was 5'-ACACCTCACGTGGGTTCCCCGTATCAT-3', and the reverse primer was 5'-CTTAACTGGTTGTCGAGG-3'. Primers for rat Runx2 were 5'-GTTATGAAAAAACCAAGTACCGAG GG T-3' (forward) and 5'-GTAATCTGACTGTGTCCTGTGGA T-3' (reverse). Primers for human Runx2 were 5'-TCTCTGACGCCCTCAGTGAT-3' (forward) and 5'-CAGAGGTGG CAGTGTCATT-3' (reverse).

Western blotting. Cartilages of the femoral head and knee joint were obtained from patients with OA. Control articular cartilages were obtained from patients with idiopathic osteonecrosis of the femoral condyle. Total protein was extracted from each sample using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) and the protein concentrations were assessed using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). Equal amounts of protein were loaded and separated discontinuously by SDS-PAGE (12% gels), and subsequently transferred onto a polyvinylidene fluoride membrane (GE Healthcare Life Sciences, Little Chalfont, UK). Membranes were blocked for 1 h at room temperature with 5% non-fat milk in Tris-buffered saline plus 0.5% Tween-20 (TBST). The membranes were incubated with primary antibodies, including anti-Runx2 (cat. no. ab76956), anti-collagen II (cat. no. ab34712), anti-collagen X (cat. no. ab49945), anti-MMP-1 (cat. no. ab52631), anti-MMP-13 (cat. no. ab39012), and anti-COMP (cat. no. ab74524) (all Abcam) overnight at 4°C. Antibodies were diluted with TBST at ratio of 1:1,000. The membrane was washed several times and incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibodies (1:200; cat. no. ab7090; Abcam) for 2 h. Following washing, blots were visualized using enhanced chemiluminescence reagent (Forevergen Biosciences, Guangzhou, China). Signals were densitometrically assessed with the gel analysis tool of ImageJ software (version 1.48v; National Institutes of Health, Bethesda, MD, USA).

Statistical analysis. For all analyses, the measurements obtained from the groups are expressed as the mean ± standard deviation. Analysis of variance followed by Tukey’s test was performed for multiple groups and Student’s t-test was applied to analyze the differences between two groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Runx2 is induced in human OA tissues where miR-204-5p is downregulated. Relative mRNA expression of Runx2 was significantly increased in OA tissues compared with necrotic bone tissues (P<0.001; Fig. 1A). Similarly, the protein expression of Runx2 was increased in OA tissues compared with necrotic bone tissues (Fig. 1B), which was revealed to be significant (P<0.01; Fig. 1C). In contrast, the relative level of miR-204-5p was significantly decreased in OA tissue samples compared with that in bone necrosis samples (P<0.001; Fig. 1D).

Overexpression of miR-204-5p downregulates Runx2 in rat primary chondrocytes and the SW-1353 human bone chondrosarcoma cell line. As presented in Fig. 2A, the relative level of miR-204-5p was significantly increased in cells transfected with miR-204-5p mimic and this expression was suppressed when its inhibitor was transfected. These results may be indicative of successful transfection; therefore, the mimic and inhibitor were qualified for follow-up examination. The relative mRNA level of Runx2 was significantly decreased.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

3
in the presence of miR-204-5p mimic compared with its NC (P<0.05), and a significant increase was detected in the presence of miR-204-5p inhibitor compared with miR-204-5p mimic (P<0.05; Fig. 2B). A similar expression pattern was also observed for Runx2 protein detected by western blot analysis (Fig. 2C and D).

Overexpression of miR-204-5p inhibits chondrocyte proliferation. Cell proliferation was significantly suppressed when miR-204-5p mimic was transfected, compared with NC, and this decrease in cell proliferation was reversed following transfection of miR-204-5p inhibitor (P<0.05) in rat primary chondrocytes (Fig. 3A) and the SW-1353 cell line (Fig. 3B).

miR-204-5p regulates the expression level of OA-associated molecules and Runx2 is a direct target of miR-204-5p. Protein expression of collagen II was increased, whereas that of collagen X, matrix metalloproteinase (MMP)-13 was decreased in miR-204-5p mimic-transfected cells compared with NC in rat primary chondrocytes and the SW-1353 cell line (Fig. 4A). These differences were revealed to be significant (P<0.05; Fig. 4B and C). These alterations in the expression level of OA-associated mediators caused by miR-204-5p mimic were reversed by miR-204-5p inhibitor (Fig. 4A-C). In addition, a putative miR-204-5p-binding site for Runx2 mRNA is presented in Fig. 4D. Relative luciferase activity was significantly decreased in the wild-type following transfection with miR-204-5p mimic, compared with NC (P<0.05). Such events were not observed in cells transfected with empty vector and/or mutant 3'-UTR-binding site of Runx2 mRNA (P>0.05; Fig. 4E).

miR-204-5p agomir attenuates the loss of articular cartilage in rats. Articular cartilage tissues of femoral condyle were stained with Safranin O/Fast Green and the cartilage was stained red, whereas the subchondral bone appeared blue. Following treatment for 10 weeks (Fig. 5A), the rats in the sham group exhibited uniform staining with Safranin O, indicating the complete structure of joint cartilage. Rats in the OA group exhibited features of OA, including surface undulations, osteophytes (positivity on the superficial layer), and appearance of hypertrophic chondrocytes (Runx2-positive) were observable in certain sections of articular cartilage in the OA group, but scarcely observed in the agomir group (data not shown). Histomorphometric analysis revealed that the thickness of cartilage was significantly decreased in the OA group (P<0.05; Fig. 5C). In addition, Mankin's score was significantly increased in the OA group (compared with the sham group) at different time points exhibited the same expression pattern with a considerably increased level in OA group and decreased level in the Sham group, whereas that in the agomir treatment group was notably decreased compared with the OA group.

miR-204-5p agomir alters the expression of OA-associated mediators in rats. At 1 day, 5 weeks, 10 weeks and 15 weeks after miR-204-5p agomir injection, relative expression levels of miR-204-5p and Runx2 were determined by western blotting. Except for no significant alteration between the sham and OA groups at 1 day, the miR-204-5p level was significantly decreased in OA group (compared with the sham group) and significantly increased in the OA+agomir group (compared with the OA group) at different time points (P<0.05; Fig. 6A). The Runx2 protein level at different time points exhibited the same expression pattern with a considerably increased level in OA group and decreased level in the OA+agomir group, and the Runx2 protein level increased with the treatment duration (Fig. 6B), which was revealed to be significant (Fig. 6C). After 10 weeks, protein expression of MMP-1, MMP-13, cartilage oligomeric matrix protein (COMP) fragment and collagen X was notably increased, whereas the expression level of collagen II and aggrecan was decreased in the OA group compared with the sham group (Fig. 6D). These alterations in OA were effectively reversed with miR-204-5p agomir treatment (Fig. 6D). Differences in the expression levels of the various proteins...
were significantly different between the treatment groups (P<0.05; Fig. 6E).

**Discussion**

In the present study, it was identified that miR-204-5p was downregulated in cartilage tissue of patients with OA where Runx2 was overexpressed. This negative-association expression pattern was also observed in SW-1353 human bone chondrosarcoma cells and rat primary chondrocytes. In order to elucidate the function of miR-204-5p, cell proliferation was determined in the two types of cell, and each cell type was divided into three different subgroups: miR-204-5p mimic, miR-204-5p inhibitor and NC. It was identified that overexpressed miR-204-5p significantly inhibited the cell proliferation in the two cell types. The well-established markers collagens II, X, MMP-1 and MMP-13 were investigated for the hypertrophic stage of chondrocyte differentiation and miR-204-5p-binding activity to Runx2. The results identified that the expression levels of these markers were significantly increased with miR-204-5p overexpression and that Runx2 was a target of miR-204-5p. At 10 and 15 weeks after the treatment, the severity of OA-like phenotype was analyzed by grading histological sections using Mankin's score system by two blinded observers in addition to examination of Runx2 protein expression and cartilage thickness. Following miR-204-5p agomir treatment, cartilage thickness was increased, whereas Mankin's score was decreased, and the number of Runx2-positive cells was also decreased. In order to elucidate further the potential function of miR-204-5p in age-associated OA, the expression levels of miR-204-5p and...
Runx2 were determined at different time points during the treatment. The agomir treatment group exhibited a significant increase in miR-204-5p expression, but a decrease in Runx2 expression. Following agomir treatment for 10 weeks, osteophyte formation was evaluated by examining the associated molecules, and a decrease in MMP-1, MMP-13, COMP fragment, collagen X, and an increase in collagen II and aggrecan were identified.

How specific miRNAs influence cartilage hemostasis and the mechanism of OA development has been the focus of previous studies (21-23). As a tumor suppressor, miR-204-5p has been intensively investigated in different diseases (24). Numerous miRNAs appear to be important modulators of chondrogenesis and OA. Their expression is frequently altered in OA, and a number are functionally implicated in the pathogenesis of the disease (25). However, the function of miR-204-5p in OA and the underlying molecular mechanism involved has not yet been investigated.

During bone development, the balance between chondrocyte proliferation and differentiation is crucial for maintaining normal bone growth and endochondral bone formation. Disturbed chondrocyte proliferation as well as hypertrophic differentiation leads to alterations in bone structure and stability (26). Runx2 serves an important function in the maturation of chondrocytes, which is a prerequisite for endochondral ossification and this is an essential process for the development of OA (27). Runx2 also serves an essential function in the differentiation of mesenchymal progenitor cells into osteoblasts, and its deficiency leads to a lack of endochondral and intramembranous bone formation because of the arrest...
of osteoblast differentiation (28,29). Runx2 expression was consistently high at all stages of chondrocyte differentiation (30). No hypertrophic cells were detected in Runx2/Runx3 double mutants. In contrast, overexpression of Runx2 is sufficient to initiate hypertrophic differentiation (31). The results of the present study indicated that rats with surgically induced

Figure 5. Representative histological staining of articular cartilage of femoral of rats from sham, OA and OA+agomir treatment groups. Safranin O/Fast Green staining (scale bar, 100 µm) and Runx2-positive staining (arrow) with immunohistochemistry (scale bar, 20 µm) at (A) 10 weeks and (B) 15 weeks after treatment (magnification, x400). (C) Assessment of relative cartilage thickness and (D) Mankin's score at 10 weeks and 15 weeks after treatment. *P<0.05, **P<0.01, ***P<0.001 vs. the sham group; †P<0.05, ††P<0.01 vs. the OA group; †††P<0.01. OA, osteoarthritis; Runx2, Runt-related transcription factor-2; NS, not significant.

Figure 6. Expression of Runx2 and OA-associated molecules at 1 day, 5 weeks, 10 weeks and 15 weeks after treatment. (A) Relative expression of miR-204-5p at different time points. (B) Runx2 protein expression at different time points. (C) Quantification of protein expression. (D) Protein expression level of COL II and X, COMP fragment, aggrecan, MMP-1 and MMP-13 at 10 weeks after treatment. (E) Quantification of protein expression. *P<0.05, **P<0.01, ***P<0.001 vs. the sham group; †P<0.05, ††P<0.01 vs. the OA group. Runx2, Runt-related transcription factor-2; OA, osteoarthritis; miR, microRNA; COL, collagen; COMP, cartilage oligomeric matrix protein; MMP, matrix metalloproteinase.
OA exhibited an OA-like phenotype as well as increased expression of Runx2 protein adjacent to the area with cartilage degradation. With miR-204-5p treatment, the severity of disease and OA degradation was ameliorated, and the Runx2 expression was decreased. In addition, it was also identified that the production of Runx2 was gradually increased as the rats aged. Therefore, we hypothesized that Runx2 may also be involved in age-associated OA (32).

In each phase of endochondral ossification, cells were subjected to consistent alteration in shapes and arrangement (2). Subsequent to undifferentiated mesenchymal progenitor cells differentiating into chondrocytes, cells commence the production of typical cartilage components, including collagens II, IX and XI, and the proteoglycan aggrecan (33). During this stage, chondrocytes maintain a low proliferation rate. Following entry of chondrocytes into the proliferation stage with several rounds of division, the cells arrange into longitudinal columns and begin to express collagen VI (34). Further differentiation into hypertrophic chondrocytes induces the production of collagen X. Finally, hypertrophic chondrocytes decrease the production of collagens II, IX and XI, and MMP-13 and transcription factor Runx2 (35). Among them, MMP-13 and collagen X are well-established markers for late chondrocyte differentiation. COMP is another important regulator in the maintenance of collagens I and II networks (36). In the present study, the expression levels of all these mediators were determined in order to elucidate the molecular mechanism accompanied by chondrocyte proliferation in OA development, and the results confirmed the anti-OA effect of miR-204-5p in the rat OA models.

In conclusion, the results of the present study identified that, by targeting Runx2, miR-204-5p decreased the chondrocyte proliferation and ameliorated the OA-like phenotype in rats with surgically induced OA, and suggested that miR-204-5p may be investigated as a novel therapeutic agent for the treatment of OA.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

XLL conceived and designed the study. JQC and XYH performed experiments and were major contributors in writing the manuscript. XQ and XYJ made significant contributions to acquisition and analysis of data. JQC and XQ performed the statistical analysis. JQC and XYH were responsible for biological samples collection. XLL revised the paper critically for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All human studies were approved by the institutional ethics review board of The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University (Shanghai, China). Written informed consent was obtained from each patient. All animal procedures were approved by the Animal Care and Use Committee of The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


